Notable earnings reports in biotech this week.
Here's why shares of Dendreon backslid today, and lost so much of yesterday's market gain.
Dendreon, AbbVie, and Omeros could all loom large in health-care headlines this morning. Here’s the news that you need to know.
Despite a lackluster quarter where it trailed rivals Johnson & Johnson and Medication, investors sent sales of Dendreon up 15%.
The S&P 500 sinks as the Ukranian crisis thickens while Plug Power, Dendreon, and Pacific Ethanol soar.
Dendreon shares soar for a change after reporting its fourth-quarter earnings results. Is this move sustainable or the perfect exit point for shareholders?
Cancer immunotherapies are all the rage on Wall Street, but these five immunotherapy-focused companies all have one big thing in common.
Amarin, Dendreon, and Prosensa are three biotech stocks which should be avoided at all costs. Here’s why.
Following a year of tracking 10 contrarian plays against the S&P 500, it's time to determine how we fared and what we learned from our experiment.
Sales of Dendreon's (DNDN) prostate drug Provenge bounced back in the fourth quarter, but the recovery may not warrant buying shares -- yet.